---
figid: PMC9924067__fonc-13-1080990-g001
figtitle: Challenges and future of HER2-positive gastric cancer therapy
organisms:
- Rattus norvegicus
- Helicobacter pylori
- Homo sapiens
organisms_ner:
- Homo sapiens
- Danio rerio
pmcid: PMC9924067
filename: fonc-13-1080990-g001.jpg
figlink: /pmc/articles/PMC9924067/figure/f1/
number: F1
caption: Mechanism of action of agents targeting HER2. Trastuzumab (green) binds to
  the ECD IV of HER2, thereby inhibiting the HER2 signaling pathway leading to cell
  cycle arrest; Pertuzumab (orange), which binds to the ECD II and Inhibits dimer
  formation; Margetuximab, which binds trastuzumab to an altered Fc-γ domain that
  involved in ADCC; Lapatinib (yellow) directly prevents the PI3K pathway from being
  activated by binding to the intracellular tyrosine kinase domain of HER2; T-DM1
  (red circle)releases the emtansine moiety after the ADC is phagocytosed by lysosomes;
  T-Dxd (orange triangle), another ADC combining trastuzumab and deruxtecan, a potent
  topoisomerase I inhibitor; Bispecific antibody ZW25 (purple) binds to both extracellular
  domains II and IV of HER-2.
papertitle: Challenges and future of HER2-positive gastric cancer therapy.
reftext: Chenzhe Ma, et al. Front Oncol. 2023;13:1080990.
year: '2023'
doi: 10.3389/fonc.2023.1080990
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.
keywords: gastric cancer | receptor ErbB-2 | HER2 | Her2 resistance | trastuzumab
automl_pathway: 0.9392418
figid_alias: PMC9924067__F1
figtype: Figure
redirect_from: /figures/PMC9924067__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9924067__fonc-13-1080990-g001.html
  '@type': Dataset
  description: Mechanism of action of agents targeting HER2. Trastuzumab (green) binds
    to the ECD IV of HER2, thereby inhibiting the HER2 signaling pathway leading to
    cell cycle arrest; Pertuzumab (orange), which binds to the ECD II and Inhibits
    dimer formation; Margetuximab, which binds trastuzumab to an altered Fc-γ domain
    that involved in ADCC; Lapatinib (yellow) directly prevents the PI3K pathway from
    being activated by binding to the intracellular tyrosine kinase domain of HER2;
    T-DM1 (red circle)releases the emtansine moiety after the ADC is phagocytosed
    by lysosomes; T-Dxd (orange triangle), another ADC combining trastuzumab and deruxtecan,
    a potent topoisomerase I inhibitor; Bispecific antibody ZW25 (purple) binds to
    both extracellular domains II and IV of HER-2.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ERBB2
  - ERBB3
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - her2
  - her3
  - rab1ab
  - mtor
  - pak2a
  - itpka
  - Ras
  - MEK
  - Nucleus
---
